Research Novo agrees $2.6B deal for Hengrui’s preclinical GLP-1/GIP drugBy Healthcare Propulsion StaffSeptember 29, 20260 Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug…
